Header menu link for other important links
X
Breast cancer biobank from a single institutional cohort in an urban setting in india: Tumor characteristics and survival outcomes
L. Busheri, S. Dixit, S. Nare, R. Alhat, G. Thomas, M. Jagtap, R. Navgire, P. Shinde, R. Banale, R. UndeShow More
Published in Elsevier Ltd
2021
PMID: 34098400
Volume: 28
   
Abstract
Background: A breast cancer biobank with retrospectively collected patient data and FFPE tissue samples was established in 2018 at Prashanti Cancer Care Mission, Pune, India. It runs a cancer care clinic with support from a single surgeon's breast cancer practice. The clinical data and tissue sample collection is undertaken with appropriate patient consent following ethical approval and guidelines. Methods: The biobank holds clinical history, diagnostic reports, treatment and follow-up information along with FFPE tumor tissue specimens, adjacent normal and, in few cases, contralateral normal breast tissue. Detailed family history and germline mutational profiles of eligible and consenting patients and their relatives are also deposited in the biobank. Results: Here, we report the first audit of the biobank. A total number of 994 patients with breast disease have deposited consented clinical records in the biobank. The majority of the records (80%, n = 799) are of patients with infiltrating ductal carcinoma (IDC). Of 799 IDC patients, 434 (55%) have deposited tumor tissue in the biobank with consent. In addition, germline mutation profiles of 84 patients and their family members are deposited. Follow-up information is available for 85% of the 434 IDC patients with an average follow-up of 3 years. Conclusion: The biobank has aided the initiation of translational research at our center in collaboration with eminent institutes like IISER Pune and SJRI Bangalore to evaluate profiles of breast cancer in an Indian cohort. The biobank will be a valuable resource to the breast cancer research community, especially to understand South Asian profiles of breast cancer. © 2021
About the journal
JournalData powered by TypesetCancer Treatment and Research Communications
PublisherData powered by TypesetElsevier Ltd
ISSN24682942